DGX vs LH vs GH
161 measures in 16 categories, one definition each, computed from filings and market data.
DGX62.3
Quest Diagnostics Incorporated
Healthcare · Medical - Diagnostics & Research
$235.00 −1.74%$25.9B mkt cap
Score DNA
LH62.1
Labcorp Holdings Inc.
Healthcare · Medical - Diagnostics & Research
$317.95 −2.19%$25.8B mkt cap
Score DNA
GH41.8
Guardant Health, Inc.
Healthcare · Medical - Diagnostics & Research
$158.60 −4.39%$21.3B mkt cap
Score DNA
Price, rebased to 100 three years ago
DGX LH GH · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 1 |
| Insider $ bought, 180d | — | — | $0.08M |
| Congress purchases, 180d | 4 | 2 | 0 |
| Last Congress purchase | 2026-09-04 | 2026-09-04 | — |
| 13F net change in holders | +42 | +27 | — |
| ETFs adding shares, 30d | 1,044 | 934 | 464 |
| ETFs trimming, 30d | 983 | 899 | 314 |
| Net ETF funds, 30d | +61 | +35 | +150 |
Valuation
16 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| P/E (TTM) | 24.4x
6th
|
25.7x
12th
|
— |
| PEG (P/E ÷ 3-yr EPS CAGR) | 2.24
12th
|
2.73
50th
|
— |
| Price / sales | 2.2x
17th
|
1.8x
10th
|
18.0x
90th
|
| Price / book | 3.5x
48th
|
3.0x
41st
|
— |
| Price / tangible book | — | — | — |
| Price / free cash flow | 21.3x
21st
|
22.3x
26th
|
— |
| Price / operating cash flow | 14.6x
9th
|
15.7x
17th
|
— |
| Enterprise value | $31.7B
66th
|
$32.4B
69th
|
$21.9B
62nd
|
| EV / sales | 2.7x
21st
|
2.3x
17th
|
18.5x
90th
|
| EV / EBITDA | 15.0x
14th
|
15.1x
19th
|
— |
| EV / EBIT | 19.3x
6th
|
22.3x
18th
|
— |
| EV / free cash flow | 26.0x
26th
|
28.1x
32nd
|
— |
| Earnings yield | 4.1%
97th
|
3.9%
93rd
|
-2.1%
24th
|
| FCF yield | 4.7%
86th
|
4.5%
83rd
|
-1.1%
24th
|
| Operating cash flow yield | 6.8%
93rd
|
6.4%
86th
|
-0.8%
17th
|
| Graham number (per share) | $119.65
88th
|
$169.90
94th
|
— |
Profitability (TTM)
12 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Gross margin | 33.1%
31st
|
27.8%
17th
|
65.0%
72nd
|
| EBITDA margin | 18.3%
55th
|
15.0%
48th
|
-34.8%
7th
|
| Operating margin | 14.1%
66th
|
11.3%
52nd
|
-39.7%
7th
|
| EBIT margin | 14.2%
66th
|
10.1%
52nd
|
-38.0%
7th
|
| Net margin | 9.2%
59th
|
7.0%
48th
|
-38.3%
7th
|
| NOPAT margin | 11.0%
59th
|
9.2%
48th
|
-31.4%
7th
|
| FCF margin | 10.6%
55th
|
8.1%
38th
|
-19.3%
14th
|
| Operating cash flow margin | 15.3%
52nd
|
11.4%
34th
|
-14.6%
14th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
31.8%
93rd
|
| SG&A / revenue | 17.5%
21st
|
15.5%
14th
|
73.0%
93rd
|
| Stock comp / revenue | 0.5%
4th
|
0.9%
18th
|
12.5%
93rd
|
| Effective tax rate | 22.6%
93rd
|
18.7%
38th
|
21.0%
52nd
|
Returns on capital
11 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| ROE (on average equity) | 14.4%
74th
|
11.7%
63rd
|
— |
| ROA | 6.5%
69th
|
5.5%
66th
|
-28.0%
3rd
|
| ROIC | 9.5%
66th
|
8.6%
62nd
|
-88.3%
3rd
|
| ROCE | 10.9%
76th
|
8.9%
69th
|
-28.6%
3rd
|
| Return on tangible assets | 10.0%
79th
|
8.0%
66th
|
-27.7%
3rd
|
| Cash ROIC (OCF / invested capital) | 13.4%
55th
|
10.8%
45th
|
-41.1%
3rd
|
| Gross profitability (GP / assets) | 22.6%
52nd
|
21.6%
45th
|
40.2%
72nd
|
| ROIC, 3-yr average | 7.1%
75th
|
5.1%
58th
|
— |
| ROIC, 5-yr average | 9.3%
79th
|
6.9%
62nd
|
— |
| ROE, 5-yr average | 15.1%
80th
|
11.0%
72nd
|
— |
| Incremental ROIC | 184.9%
89th
|
196.1%
93rd
|
-10.0%
44th
|
Growth
17 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Revenue growth (TTM YoY) | 9.9%
61st
|
6.4%
36th
|
42.7%
96th
|
| Revenue growth (QoQ) | 5.1%
24th
|
5.5%
34th
|
11.0%
72nd
|
| Revenue CAGR, 3 yr | 6.8%
56th
|
4.4%
44th
|
32.4%
96th
|
| Revenue CAGR, 5 yr | 0.9%
26th
|
-2.6%
15th
|
29.6%
93rd
|
| Gross profit CAGR, 3 yr | 6.3%
59th
|
4.0%
44th
|
34.6%
93rd
|
| Operating income CAGR, 3 yr | 11.5%
67th
|
15.1%
87th
|
— |
| Net income growth (TTM YoY) | 11.8%
50th
|
31.3%
81st
|
— |
| Net income CAGR, 3 yr | 10.3%
83rd
|
6.5%
42nd
|
— |
| EPS growth (TTM YoY) | 12.8%
38th
|
34.7%
81st
|
— |
| EPS CAGR, 3 yr | 10.9%
75th
|
9.4%
58th
|
— |
| EPS CAGR, 5 yr | -11.7%
21st
|
-16.1%
14th
|
— |
| FCF growth (TTM YoY) | -0.3%
33rd
|
-8.4%
28th
|
— |
| FCF CAGR, 3 yr | 11.6%
64th
|
2.6%
36th
|
— |
| Operating cash flow CAGR, 3 yr | 8.9%
59th
|
3.2%
35th
|
— |
| Book value CAGR, 3 yr | 7.0%
72nd
|
2.1%
44th
|
— |
| Dividend CAGR, 3 yr | 2.6%
60th
|
2.3%
40th
|
— |
| Sustainable growth rate | 9.5%
44th
|
8.9%
38th
|
— |
Margin history & stability
7 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Gross margin, 3-yr average | 33.0%
29th
|
28.0%
14th
|
70.0%
96th
|
| Operating margin, 3-yr average | 13.9%
68th
|
8.7%
50th
|
-58.3%
7th
|
| Net margin, 3-yr average | 9.1%
71st
|
5.4%
54th
|
-54.8%
7th
|
| FCF margin, 3-yr average | 10.5%
50th
|
8.1%
46th
|
-32.9%
7th
|
| Revenue stability (0-1) | 0.03
0th
|
0.22
11th
|
0.91
64th
|
| Earnings stability (0-1) | 0.51
61st
|
0.60
68th
|
0.00
0th
|
| Margin stability (0-1) | 0.90
46th
|
0.84
18th
|
0.88
29th
|
Liquidity (latest quarter)
7 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Cash & short-term investments | $626.0M
59th
|
$141.8M
10th
|
$1.1B
79th
|
| Net cash (− = net debt) | −$5.8B
14th
|
−$6.6B
10th
|
−$643.5M
55th
|
| Working capital | $1.1B
72nd
|
$1.7B
86th
|
$1.0B
69th
|
| Current ratio | 1.59
28th
|
1.80
34th
|
4.03
76th
|
| Quick ratio | 1.46
34th
|
1.53
45th
|
3.71
76th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.35
28th
|
0.07
3rd
|
3.11
76th
|
| Defensive interval (days) | 381 days
34th
|
406 days
38th
|
353 days
28th
|
Leverage & solvency (latest quarter)
13 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Total debt | $6.4B
86th
|
$6.8B
90th
|
$1.7B
52nd
|
| Debt / equity | 0.85
81st
|
0.79
74th
|
— |
| Net debt / equity | 0.77
81st
|
0.77
85th
|
— |
| Debt / assets | 37.7%
76th
|
36.5%
69th
|
88.7%
100th
|
| Debt / capital | 45.9%
79th
|
44.0%
71st
|
— |
| Debt / EBITDA | 3.02
43rd
|
3.14
48th
|
— |
| Net debt / EBITDA | 2.72
52nd
|
3.08
62nd
|
— |
| Interest coverage (EBIT / interest) | 6.3x
68th
|
6.4x
72nd
|
−93.4x
8th
|
| Cash interest coverage | 6.8x
52nd
|
7.2x
56th
|
−35.9x
8th
|
| Debt payback (years of OCF) | 3.6 yrs
48th
|
4.1 yrs
61st
|
— |
| Liabilities / assets | 53.8%
72nd
|
53.5%
69th
|
111.7%
100th
|
| IS credit model rating | A | A | B- |
| Implied credit spread (bps) | 150
34th
|
150
34th
|
900
97th
|
Efficiency
11 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Asset turnover | 0.70
66th
|
0.78
76th
|
0.73
72nd
|
| Fixed asset turnover | 3.99
41st
|
4.63
59th
|
3.91
38th
|
| Inventory turnover | 36.8
100th
|
19.3
92nd
|
4.4
36th
|
| Receivables turnover | 7.5
79th
|
6.4
45th
|
8.7
86th
|
| Days sales outstanding | 49 days
21st
|
57 days
55th
|
42 days
14th
|
| Days inventory outstanding | 10 days
0th
|
19 days
8th
|
84 days
64th
|
| Days payables outstanding | 31 days
38th
|
26 days
28th
|
61 days
83rd
|
| Cash conversion cycle (days) | 28 days
7th
|
50 days
24th
|
64 days
45th
|
| Capex / revenue | 4.8%
69th
|
3.4%
48th
|
4.7%
66th
|
| Capex / depreciation | 1.18
83rd
|
0.69
52nd
|
1.44
90th
|
| Operating expense ratio | 18.7%
14th
|
17.7%
10th
|
103.9%
93rd
|
Cash flow & earnings quality
7 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Operating cash flow / net income | 1.67
71st
|
1.63
59th
|
— |
| FCF / net income | 1.15
53rd
|
1.15
59th
|
— |
| FCF / operating cash flow | 68.8%
35th
|
70.5%
39th
|
— |
| Capex / operating cash flow | 31.2%
65th
|
29.5%
61st
|
— |
| Accruals ratio | -4.3%
48th
|
-3.5%
66th
|
-17.3%
7th
|
| Sloan accruals ratio | 2.5%
69th
|
-2.1%
45th
|
21.1%
100th
|
| Earnings quality score (0-1) | 1.00
24th
|
1.00
24th
|
— |
Scores & forensic checks
15 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| IS score | 62
69th
|
62
66th
|
42
34th
|
| IS profitability | 46
62nd
|
37
52nd
|
20
34th
|
| IS growth | 55
50th
|
62
61st
|
63
68th
|
| IS value | 53
86th
|
53
90th
|
32
17th
|
| IS momentum | 83
75th
|
89
89th
|
59
32nd
|
| IS risk (safety) | 80
38th
|
80
38th
|
90
59th
|
| IS quality | 75
76th
|
73
66th
|
38
3rd
|
| IS balance sheet | 51
52nd
|
50
48th
|
0
0th
|
| IS earnings quality | 77
93rd
|
76
83rd
|
36
7th
|
| IS cash flow | 55
55th
|
51
52nd
|
30
21st
|
| Piotroski F-score (0-9) | 8
76th
|
8
76th
|
6
41st
|
| Altman Z-score | 3.5
55th
|
3.2
38th
|
3.7
59th
|
| Beneish M-score | −2.51
79th
|
−2.52
71st
|
−2.85
18th
|
| Ohlson O-score | −8.23
48th
|
−8.31
45th
|
−4.73
100th
|
| IS credit score | 70
59th
|
71
62nd
|
20
0th
|
Size (TTM)
8 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| Market cap | $25.9B
69th
|
$25.8B
66th
|
$21.3B
62nd
|
| Revenue | $11.6B
86th
|
$14.3B
90th
|
$1.2B
38th
|
| EBITDA | $2.1B
86th
|
$2.2B
90th
|
−$411.2M
0th
|
| Net income | $1.1B
83rd
|
$1.0B
79th
|
−$453.4M
0th
|
| Free cash flow | $1.2B
79th
|
$1.2B
76th
|
−$228.4M
3rd
|
| Total assets | $16.9B
83rd
|
$18.5B
86th
|
$1.9B
34th
|
| Shareholders' equity | $7.5B
83rd
|
$8.6B
86th
|
−$222.9M
0th
|
| Employees | 51,500
86th
|
71,000
93rd
|
2,498
31st
|
Price performance
9 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| 1 day | −1.7% | −2.2% | −4.4% |
| 1 week | +1.7% | +1.9% | −5.3% |
| 1 month | −5.0% | −1.5% | −13.4% |
| 3 months | +13.2% | +13.2% | +7.1% |
| 6 months | +20.5% | +18.0% | +75.5% |
| Year to date | +35.8% | +27.3% | +55.9% |
| 1 year | +25.4% | +13.6% | +147.1% |
| 3 years, cumulative | +99.3% | +64.7% | +452.0% |
| 5 years, cumulative | +79.3% | +40.2% | +42.1% |
Technicals
4 measures| Measure | DGX | LH | GH |
|---|---|---|---|
| RSI 14 | 51.1 | 53.1 | 39.6 |
| From 52-week high | −5.5% | −6.8% | −17.0% |
| From 52-week low | +37.9% | +31.4% | +147.8% |
| Beta | 0.54 | 0.85 | 1.58 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17